Evelyn Cordero
Family Medicine · Bronx, NYNPI 1003823584
Payments from drug & device makers
Across 220 payments — averaging $22.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Lilly USA, LLC$817
- GSK$788
- Bayer$730
- Novo Nordisk$392
- Boehringer Ingelheim$304
- plus $721 from 11 others
What the payments were for
- Food & beverage$5,00099%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 66 | $1,294 |
| Lilly USA, LLC | 39 | $817 |
| GSK | 29 | $788 |
| Bayer | 31 | $730 |
| Novo Nordisk | 11 | $392 |
| Boehringer Ingelheim | 7 | $304 |
| Astellas Pharma US Inc | 7 | $139 |
| Pfizer | 7 | $138 |
| Merck | 5 | $94 |
| Amgen(2 entities) | 5 | $88 |
| EMD Serono, Inc. | 3 | $80 |
| Novartis | 3 | $68 |
| Amarin Pharma, Inc. | 3 | $42 |
| Althera Pharmaceuticals LLC | 1 | $22 |
| Eyevance Pharmaceuticals LLC | 1 | $20 |
| Dexcom, Inc. | 1 | $18 |
| Abbott | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,045 in reported general payments places this provider in the 85th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 86 | $95,754 |
| JardianceEmpagliflozin | 58 | $57,269 |
| OzempicSemaglutide | 42 | $51,852 |
| FarxigaDapagliflozin Propanediol | 48 | $48,988 |
| XareltoRivaroxaban | 36 | $34,463 |
| EliquisApixaban | 35 | $30,239 |
| JanuviaSitagliptin Phosphate | 36 | $29,788 |
| LinzessLinaclotide | 39 | $23,621 |
| TrulicityDulaglutide | 14 | $22,839 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $18,235 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $17,103 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 33 | $10,182 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 20 | $6,130 |
| Wixela InhubFluticasone Propion/Salmeterol | 18 | $1,629 |
| Atorvastatin Calcium | 190 | $1,624 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerKerendia | $730 | $95,75486 claims |
| Boehringer IngelheimJardiance | $304 | $57,26958 claims |
| Novo NordiskOzempic | $392 | $51,85242 claims |
| AstraZenecaFarxiga | $1,294 | $48,98848 claims |
| MerckJanuvia, Janumet | $94 | $48,02347 claims |
| PfizerEliquis | $138 | $30,23935 claims |
| Lilly USA, LLCTrulicity | $817 | $22,83914 claims |
| GSKTrelegy Ellipta | $788 | $17,10320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,321 family medicine providers in New York.
Other family medicine in Bronx
- Eugene SchiffBronx$184K
- Hui-Li HuangBronx$41K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.